A pharmaceutical composition is provided which contains a phospholipid-containing composition which antagonizes toll-like receptors 1, 2, 3, 6, 7, 8 and 10. The phospholipid-containing composition consists of regioisomers and stereoisomers of palmitoyloleoylphosphatidylglycerol (POPG) consisting of at least 80% of 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-(1′-rac-glycerol) or a salt thereof, and no more than 20% of its regioisomer 1-oleoyl-2-palmitoyl-sn-glycero-3-phospho-(T-rac-glycerol) or a salt thereof. The phospholipid-containing composition also has enantiomeric enrichment with at least 51% of the dextro rotatory isomer at the sn-2 position of the terminal glycerol moiety.

The present disclosure relates to a pharmaceutical composition for preventing or treating statin-induced adverse effects or a pharmaceutical composition for co-administration with statin, the pharmaceutical composition containing, as an active ingredient, at least one selected from the group consisting of an isoprenoid-based compound, zaragozic acid, terbinafine, and ketoconazole. The pharmaceutical composition according to the present disclosure may prevent and/or treat adverse statin effects that can be induced by statin, that is, can be induced at any time by oxisterols present at abnormal levels in the body. The pharmaceutical composition can not only treat but also prevent the adverse effects of various statin therapeutics whose use has recently increased rapidly, and thus it is expected that the pharmaceutical composition can be widely used for various diseases and the utilization thereof can further be increased.

The present disclosure relates to a pharmaceutical composition for preventing or treating statin-induced adverse effects or a pharmaceutical composition for co-administration with statin, the pharmaceutical composition containing, as an active ingredient, at least one selected from the group consisting of an isoprenoid-based compound, zaragozic acid, terbinafine, and ketoconazole. The pharmaceutical composition according to the present disclosure may prevent and/or treat adverse statin effects that can be induced by statin, that is, can be induced at any time by oxisterols present at abnormal levels in the body. The pharmaceutical composition can not only treat but also prevent the adverse effects of various statin therapeutics whose use has recently increased rapidly, and thus it is expected that the pharmaceutical composition can be widely used for various diseases and the utilization thereof can further be increased.

A composition comprising curcumin, resveratrol, quercetin and inositol hexaphosphate. The composition has potential utility in treating high blood sugar, diabetes, heart disease and other chronic conditions including fibromyalgia and colitis, as well as cancer and arthritis. The composition also has potential utility in reducing inflammation, promoting weight loss, increasing energy levels, stimulating the immune system, increasing antioxidant levels, and preventing ageing.

A composition comprising curcumin, resveratrol, quercetin and inositol hexaphosphate. The composition has potential utility in treating high blood sugar, diabetes, heart disease and other chronic conditions including fibromyalgia and colitis, as well as cancer and arthritis. The composition also has potential utility in reducing inflammation, promoting weight loss, increasing energy levels, stimulating the immune system, increasing antioxidant levels, and preventing ageing.

A composition comprising curcumin, resveratrol, quercetin and inositol hexaphosphate. The composition has potential utility in treating high blood sugar, diabetes, heart disease and other chronic conditions including fibromyalgia and colitis, as well as cancer and arthritis. The composition also has potential utility in reducing inflammation, promoting weight loss, increasing energy levels, stimulating the immune system, increasing antioxidant levels, and preventing ageing.

Compounds of the general formula

##STR00001##

are disclosed with activity towards treating diseases related to inflammation, such as cancer, neurodegenerative and cardiovascular diseases. Pharmaceutical compositions and methods of use are also described.

Compounds of the general formula

##STR00001##

are disclosed with activity towards treating diseases related to inflammation, such as cancer, neurodegenerative and cardiovascular diseases. Pharmaceutical compositions and methods of use are also described.

Embodiments of the present disclosure include anti-inflammatory compositions and methods of use thereof. The compositions include purified lipids from Francisella, for example, virulent strains of Francisella. Other features and advantages of the invention will be apparent from the detailed description, and from the claims.

Embodiments of the present disclosure include anti-inflammatory compositions and methods of use thereof. The compositions include purified lipids from Francisella, for example, virulent strains of Francisella. Other features and advantages of the invention will be apparent from the detailed description, and from the claims.